Xconomy | Seattle - Business + Technology in the Exponential Economy

Sound Pharmaceuticals Applies to Test Drug Against Chemo-Induced Hearing Loss

Sound Pharmaceuticals said today it has filed an application to run a clinical trial of an experimental drug for hearing loss caused by cancer chemotherapy. The privately held Seattle biotech company said it plans to test the compound, ebselen, in patients with advanced lung cancer and head and neck tumors who received platinum-based chemotherapy. It is the second clinical program for Sound, which is testing the ebselen product with the U.S. Navy to prevent and treat hearing loss caused by loud noises.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments (1) | Reprints | Share:

Reader Comments

Bev
2/27/09 10:03 am

In regards to your article “Sound Pharmaceuticals Applies to Test Drug Against Chemo-Induced Hearing Loss” I think Dr Jonathan Kil and his team at Sound Pharmaceuticals are very intelligent people who’s hard efforts and accomplishments are greatly appreciated.